In this review:
PSMA PET-MRI vs PSMA PET-CT or mpMRI for localising primary prostate cancers
Prognostic value of a circulating AR-V based gene signature in metastatic CRPC
Targeting the AR with thiosemicarbazone anticancer agents to overcome development of resistance in prostate cancer
Transperineal biopsy vs transrectal biopsy for predicting final Gleason score
MRI for active surveillance of localised prostate cancer
CyberKnife robotic radiotherapy for localised prostate cancer
Oncological outcomes from definitive radiotherapy with hydrogel spacers
Feasibility and patient satisfaction with a pre-habilitation program
Please login below to download this issue (PDF)